Autoimmune disease and risk for Parkinson disease: A population-based case-control study

Neurology

Volumn 73, Issue 18, 2009, Pages 1462-1468

  Rugbjerg, Kathrine ^a   Friis, S ^a   Ritz, B ^b   Schernhammer, E S ^c,d   Korbo, L ^e   Olsen, J H ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHANNING LABORATORY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BIRTH; CELL ACTIVATION; CONTROLLED STUDY; DENMARK; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROGLIA; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEX DIFFERENCE;

EID: 70449345919     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c06635     Document Type: Article

References (30)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
2. Pfeiffer RF. Non-motor parkinsonism. Parkinsonism Relat Disord 2007;13:S211-S220.
3. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
4. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurode-generative disease. Brain Behav Immun 2004;18:407-413.
5. Zabriskie JB. Essential Clinical Immunology. Cambridge: Cambridge University Press; 2009.
6. Kogure T, Tatsumi T, Yuka K, Koich O. Rheumatoid arthritis accompanied by Parkinson's disease. J Clin Rheu-matol 2008;14:192-193.
7. Kunas RC, McRae A, Kesselring J, Villiger PM. Antido-paminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. J Allergy Clin Immunol 1995;96:688-690.
8. García-Moreno JM, Chacón J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord 2002;17:1329-1335.
9. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkin-sonian patients. Neurosci Lett 1994;180:147-150.
10. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994;165:208-210.
11. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;414:94-97.
12. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008;167:90-95.
13. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
14. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963-967.
15. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Non-steroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836-1842.
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Ol-sen JH. The Danish National Hospital Register: A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
18. Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ 2008; 337:a2494.
19. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321-1330.
20. Mellemkjaer L, Pfeiffer RM, Engels EA, et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008;58:657-666.
21. Carvey PM, Chen EY, Lipton JW, et al. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J Neural Transm 2005;5:601-612.
22. Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Prect Rheumatol 2007;3:707-715.
23. Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006;66:1097-1099.
24. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964-969.
25. Etminan M, Carleton BC, Samii A. Non-steroidal antiinflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008;15:576-577.
26. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88-95.
27. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478.
28. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-KB activation. Science 1996;274:1383-1385.
29. Daoud KF, Jackson CG, Williams HJ. Basic therapy for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs. Compr Ther 1999;25:427-433.
30. Kelley WN, Harris ED, Ruddy S, Sledge CB. Textbook of Rheumatology. Oxford: WB Saunders Co.; 2008